Status:
COMPLETED
A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Lead Sponsor:
Pfizer
Conditions:
Falciparum Malaria
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The treatment of symptomatic, uncomplicated malaria caused by P. falciparum in adults.
Eligibility Criteria
Inclusion
- Males and females greater then or equal to the age of 18 with uncomplicated, symptomatic malaria as indicated by the presence of blood smears positive for P. falciparum asexual parasitemia between 1000-100,000 parasites/uL and documented fever greater then or equal to 38.5 C/101.3 F rectal or fever greater then or equal to 38 C/100.4 F oral or history of fever as reported by subject within the prior 24 hours.
Exclusion
- Subjects with severe or complicated malaria. Pregnant or breast feeding women.
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00282919
Start Date
March 1 2006
End Date
February 1 2008
Last Update
June 26 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tumaco, Departamento de Nariño, Colombia
2
Pfizer Investigational Site
Bambolim, Goa, India, 403002